Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Fever

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,205 result(s) found for: Fever. Displaying page 1 of 61.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2023-000134-15 Sponsor Protocol Number: DEN-302 Start Date*: 2023-09-22
    Sponsor Name:Takeda
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Safety and Immunogenicity of a Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) Administered Subcutaneously to He...
    Medical condition: Dengue
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10012310 Dengue fever PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2018-003979-34 Sponsor Protocol Number: DEN-301 Start Date*: 2018-12-13
    Sponsor Name:Takeda Vaccines, Inc.
    Full Title: Phase III, Double-Blind, Randomized, Placebo-Controlled Trial to Investigate the Efficacy, Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TDV) Administered Subcutaneously in Healthy C...
    Medical condition: The main purpose of this study is to evaluate the efficacy of 2 doses of Tetravalent Dengue Vaccine Candidate (TDV) in preventing symptomatic dengue fever of any severity and due to any of the four...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10012312 Dengue fever virus infection LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-003455-33 Sponsor Protocol Number: INV-DEN-203 Start Date*: 2022-12-21
    Sponsor Name:Takeda Vaccines, Inc.
    Full Title: A Double-Blind, Randomized, Placebo-Controlled, Age Descending and Expansion Phase 2 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteer...
    Medical condition: Dengue Fever
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10012312 Dengue fever virus infection LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-003339-24 Sponsor Protocol Number: DEN-308 Start Date*: 2022-12-21
    Sponsor Name:Takeda Vaccines, Inc.
    Full Title: A Phase 3, Open-Label, Randomized Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) and an Intramuscu...
    Medical condition: Dengue fever
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10012312 Dengue fever virus infection LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2024-000341-27 Sponsor Protocol Number: DEN-324 Start Date*: 2024-12-13
    Sponsor Name:Takeda
    Full Title: A Randomized, Double-Blind, Placebo-Controlled (Participants aged 18 to 60 years) and Open-Label (Participants aged 4 to 17 years), Phase 2/3 Trial to Evaluate the Immunogenicity and Safety of 2 do...
    Medical condition: Dengue fever
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10012312 Dengue fever virus infection LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2012-001333-14 Sponsor Protocol Number: CCOA566B2303 Start Date*: 2012-03-09
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, investigator-blinded, multicenter, parallel group study to compare efficacy, safety and tolerability of Coartem® dispersible tablet formulation vs. Coartem® 6-dose crushed tablet in t...
    Medical condition: This study will evaluate the safety and efficacy of artemether-lumefantrine against uncomplicated malaria caused by Plasmodium falciparum in children.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10025487 Malaria PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-004505-13 Sponsor Protocol Number: TOFFIFE Start Date*: 2017-11-27
    Sponsor Name:University Hospital Tuebingen
    Full Title: Tocilizumab for the Treatment of Familial Mediterranean Fever – A randomized, doubleblind, phase II proof of concept study-TOFFIFE
    Medical condition: Adult patients with Familial Mediterranean Fever, who have active disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10016207 Familial mediterranean fever PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005852-33 Sponsor Protocol Number: CCOA566B2306 Start Date*: 2016-04-11
    Sponsor Name:Novartis Pharma AG
    Full Title: An open-label, single-arm study to evaluate the efficacy, safety and PK of artemether-lumefantrine Dispersible Tablet in the treatment of acute uncomplicated Plasmodium falciparum malaria in infant...
    Medical condition: The purpose of the study is to obtain efficacy, safety and pharmacokinetic (PK) data following treatment with artemether-lumefantrine dispersible tablet in infants < 5 kg of body weight (BW) with u...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10025487 Malaria PT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-000643-25 Sponsor Protocol Number: 205520003 Start Date*: 2011-04-19
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: The Qure study: Q-fever fatigue syndrome - response to treatment
    Medical condition: Q fever fatigue syndrome (QFS) is one of the most frequent sequelae of Q fever. QFS leads to substantial morbidity, a high socio-economic burden and an increased use of healthcare facilities. QFS: ...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10037688 Q fever PT
    14.0 10018065 - General disorders and administration site conditions 10008874 Chronic fatigue syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-003527-57 Sponsor Protocol Number: CACZ885DTR01 Start Date*: 2016-04-14
    Sponsor Name:Novartis Pharmaceuticals
    Full Title: An Open-label, Exploratory Study to Establish the Safety and Efficacy of 3 Months Treatment With Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever
    Medical condition: Familial Mediterranean Fever
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10016207 Familial mediterranean fever PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-004461-85 Sponsor Protocol Number: CCOA556B2401 Start Date*: 2016-04-06
    Sponsor Name:Novartis Pharma AG
    Full Title: A cluster randomized, single-centre, controlled, parallel,12-month prospective study and additional 12-month follow-up in Africa of malaria incidence in a community setting following systematic tre...
    Medical condition: This study assessed the impact of the systematic detection by Rapid Diagnostic Test (RDT) and treatment of asymptomatic carriers of malaria parasites (P. falciparum) with COA566 on the number of cl...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10025487 Malaria PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-003522-13 Sponsor Protocol Number: CACZ885D2204 Start Date*: 2016-04-14
    Sponsor Name:Novartis Pharmaceuticals
    Full Title: A 6 Month Phase 2, Multi-Center, Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Treatment With Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resist...
    Medical condition: Colchicine Resistant/Intolerant Familial Mediterranean Fever
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10016207 Familial mediterranean fever PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-003868-25 Sponsor Protocol Number: DEN-03-IB Start Date*: 2024-04-22
    Sponsor Name:Instituto Butantan
    Full Title: Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Dengue 1,2,3,4 (Attenuated) Vaccine produced by Instituto Butantan
    Medical condition: Dengue
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10012309 Dengue LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2019-004037-17 Sponsor Protocol Number: 19_RIPH1_07 Start Date*: 2021-07-28
    Sponsor Name:Centre Hospitalier Universitaire de Martinique
    Full Title: Multicenter, randomized, open-label non-inferiority trial, comparing two antibiotic therapy periods (3 versus 7 days) in patients with mild leptospirosis and seen at the hospital in 5 French overse...
    Medical condition: Mild Leptospirosis : defined as Leptospirosis without the following severity criteria : a. Hemodynamic failure* with onset of septic shock b. Hematologic failure* with hemoglobin requiring red blo...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10024238 Leptospirosis PT
    20.0 10021881 - Infections and infestations 10024241 Leptospirosis, unspecified LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005566-33 Sponsor Protocol Number: VYF03 Start Date*: 2021-07-08
    Sponsor Name:Sanofi Pasteur
    Full Title: Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to Stamaril® in Adults
    Medical condition: Prevention of yellow fever
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10048240 Yellow fever PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FI (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001071-23 Sponsor Protocol Number: DEN-314 Start Date*: 2018-03-26
    Sponsor Name:Takeda Vaccines, Inc.
    Full Title: A Randomized, Observer Blind, Phase 3 Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Tetravalent Dengue Vaccine Candidate (TDV) and an Intramuscular H...
    Medical condition: Healthy Volunteers "Vaccination against Dengue Fever and co-administration with Hepatitis A vaccine"
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10012312 Dengue fever virus infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-005735-40 Sponsor Protocol Number: BCG-EHMI Start Date*: 2016-03-29
    Sponsor Name:Radboud university medical center
    Full Title: Safety and protective efficacy of BCG vaccination against controlled human malaria infection
    Medical condition: Plasmodium faciparum malaria prevention
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004865 10036655 Prevention of malaria LLT
    18.1 10021881 - Infections and infestations 10025487 Malaria PT
    18.1 10021881 - Infections and infestations 10016171 Falciparum malaria LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-004163-21 Sponsor Protocol Number: A0661157 Start Date*: 2015-04-06
    Sponsor Name:Pfizer Inc
    Full Title: Phase 2/3, Open-Label, Comparative Trial Of Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In Children In Africa
    Medical condition: Malaria
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10025487 Malaria PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-003456-13 Sponsor Protocol Number: DEN-313 Start Date*: 2022-12-21
    Sponsor Name:Takeda Vaccines, Inc.
    Full Title: An Open Label, Phase 2 Study to Investigate Cell-mediated Immunity and Safety of a Tetravalent Dengue Vaccine Candidate (TDV) Administered Subcutaneously in Healthy Children Aged 4 to 16 Years
    Medical condition: Dengue fever
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10012312 Dengue fever virus infection LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-000381-35 Sponsor Protocol Number: OVG 2011/02 Start Date*: 2011-09-26
    Sponsor Name:University of Oxford
    Full Title: Understanding typhoid disease after vaccination: a single centre, randomised, double-blind, placebo-controlled study to evaluate M01ZH09 in a healthy adult challenge model, using Ty21a vaccine as a...
    Medical condition: Active immunisation for the prevention of typhoid infection in healthy adults.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10045275 Typhoid fever PT
    14.0 10021881 - Infections and infestations 10045272 Typhoid LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 23:25:58 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA